Patents Assigned to Mitsubishi Tanabe Pharma Corporation
  • Publication number: 20220298118
    Abstract: Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.
    Type: Application
    Filed: July 26, 2019
    Publication date: September 22, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Taichi TAKAHASHI, Hisayuki TAKAMATSU, Daisuke llJIMA, Shuzo TAKEDA
  • Publication number: 20220252569
    Abstract: A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 ?g/mL to 10 ?g/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value.
    Type: Application
    Filed: April 27, 2022
    Publication date: August 11, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takeshi WAKASUGI, Aya SANO
  • Publication number: 20220228140
    Abstract: An object of the present invention is to provide a compound, a method and a pharmaceutical composition for normalizing double homeobox 4 (DUX4) of an individual in which the DUX4 gene has abnormally expressed. Provided is a modified oligonucleotide consisting of 12-30 residues. The modified oligonucleotide includes a nucleobase sequence that includes at least 8 contiguous nucleobase sequences and is complementary to an equal length portion at positions 126-147, 232-248, 1306-1325 or 1472-1495 from a 5? end of a nucleobase of a mature mRNA of DUX4 of SEQ ID NO: 1. The nucleobase sequence of the modified oligonucleotide has at least 90% complementarity to the equal length portion in the nucleobase sequence of the mature mRNA of DUX4 of SEQ ID NO: 1.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 21, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Shinji KUMAGAI, Takashi YASHIRO, Tomo ARAKI, Takayuki KANAGAWA, Chieko OKAGAKI, Hiroyuki FURUKAWA
  • Publication number: 20220168314
    Abstract: A medicament for prophylaxis or treatment of pulmonary fibrosis containing as an active ingredient a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 2, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Anthony AZZARA, Kohei KIKKAWA
  • Patent number: 11339135
    Abstract: The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 24, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takafumi Yamagami, Souta Yamasaki, Tomofumi Setsuta, Ryo Sakakibara, Yosuke Matsumura
  • Publication number: 20220142982
    Abstract: A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
    Type: Application
    Filed: December 29, 2021
    Publication date: May 12, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Hidetoshi SHIMIZU, Yoshinobu NAKAMARU, Yukiko NISHIMURA
  • Publication number: 20220119364
    Abstract: The present invention provides a process for preparing a compound represented by formula (VII), which comprises reacting a compound represented by formula (VI) with a malonic acid derivative in the presence of a base and an asymmetric catalyst in a two layer solvent system of hydrophobic solvent and water.
    Type: Application
    Filed: June 10, 2021
    Publication date: April 21, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takao TESHIMA, Takafumi YAMAGAMI, Tetsuo YAMAGUCHI, Junki ANDO
  • Publication number: 20220110915
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tetsuo HAYAMA, Tomohiro TAKAHASHI, Tomoyuki OMURA, Kouji HAYASHI, Munetomo MATSUDA, Tadashi MIYAZAWA
  • Patent number: 11299547
    Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 12, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Vincent Blot, Marco Gymnopoulos, Anjuli Timmer, Ryo Fujita, Roland Newman
  • Patent number: 11285160
    Abstract: The present invention provides a pharmaceutical composition for prophylaxis and treatment of NAFLD comprising as an active ingredient a 1,4-benzoxazine compound represented by formula (I): or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, as well as a method for prophylaxis and treatment of NAFLD which comprises administering a therapeutically effective amount of the above-mentioned 1,4-benzoxazine compound represented by formula (I) and so on to a patient in need thereof.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: March 29, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Michael P. Cooreman, Kohei Kikkawa
  • Publication number: 20220082543
    Abstract: A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 ?g/mL to 10 ?g/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value.
    Type: Application
    Filed: November 29, 2021
    Publication date: March 17, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takeshi WAKASUGI, Aya SANO
  • Publication number: 20220073497
    Abstract: The present invention provides a crystal of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 10, 2022
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Naoko UEDA, Hiroomi NAGATA, Takahiro YOSHIDA
  • Publication number: 20220047551
    Abstract: The invention provides a method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof by administering an agent containing, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, to a patient that complies with specific criteria. The agent is administered by repeating a 14-day administration period and a 14-day drug holiday period, or by establishing an initial 14-day administration period and an initial 14-day drug holiday period and then repeating an administration period for 10 out of 14 days and a 14-day drug holiday period.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 17, 2022
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventor: Takatomo YONEOKA
  • Patent number: 11241416
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 8, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tetsuo Hayama, Tomohiro Takahashi, Tomoyuki Omura, Kouji Hayashi, Munetomo Matsuda, Tadashi Miyazawa
  • Patent number: 11242403
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 8, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Robyn Richardson, Anjuli Timmer, Roland Newman
  • Publication number: 20220002336
    Abstract: The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. The present invention provides specifically a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification) or salts thereof; as well as an oligonucleotide compound represented by general formula (I?) (wherein each symbol is the same as defined in the specification) or salts thereof.
    Type: Application
    Filed: November 11, 2019
    Publication date: January 6, 2022
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY
    Inventors: Hiroaki SAWAMOTO, Shinji KUMAGAI, Hiroyuki FURUKAWA, Tomo ARAKI, Masayuki UTSUGI, Satoshi OBIKA
  • Publication number: 20210393765
    Abstract: Nucleic acids encoding rotavirus VP7 fusion proteins and rotavirus-like particle (RLPs) comprising the rotavirus VP7 fusion proteins are provided. Methods for rotavirus VP7 fusion protein and RLP production in plants are also described. The VP7 fusion protein comprises a first sequence encoding a 7-1a subdomain, a second sequence encoding a 7-2 domain and a third sequence encoding a 7-1b subdomain; wherein the sequence of the 7-2 domain is derived from a first rotavirus strain and the sequence of the 7-1a subdomain, the sequence of the 7-1b subdomain or the sequence of the 7-1a subdomain and the sequence of the 7-1b subdomain are derived from a second rotavirus strain.
    Type: Application
    Filed: February 19, 2020
    Publication date: December 23, 2021
    Applicants: MEDICAGO INC., MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Marc-Andre D AOUST, Pierre-Olivier LAVOIE
  • Publication number: 20210380541
    Abstract: The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof.
    Type: Application
    Filed: November 29, 2017
    Publication date: December 9, 2021
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takafumi YAMAGAMI, Souta YAMASAKI, Tomofumi SETSUTA, Ryo SAKAKIBARA, Yosuke MATSUMURA
  • Publication number: 20210321929
    Abstract: The present disclosure provides a brain wave analysis device with a computation section configured to compute a first ratio and a second ratio from a spectrum obtained by performing frequency analysis on time-series data of brain waves measured at a predetermined location of a head of a subject.
    Type: Application
    Filed: October 15, 2019
    Publication date: October 21, 2021
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventors: Toshihiro Hosaka, Hiroshi Sato, Makoto Tamura, Ryuta Saito
  • Publication number: 20210300902
    Abstract: The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 30, 2021
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Joji TSURUMOTO, Kenji MOROKUMA